Abstract
Psoriasis is a chronic skin disorder that affects approximately 2% of the US and European population. Over the last several years, one of the major focuses in psoriasis research has been the development of biologic therapies for this disease. The aim of these therapies is to provide selective, immunologically directed intervention with fewer side effects than traditional therapies. The goal of this article is to review the progress of the biologic agents which are available, or under investigation for clinical use: infliximab, etanercept, efalizumab, alefacept, and adalimumab. In addition, two other investigational therapies, oral tazarotene and oral pimecrolimus will be discussed. Clinical data for these agents, including the most recent phase II and / or III study results, will be discussed, as well as the most recent safety data
Keywords: psoriasis, biologic therapy, t cell, cytokine, infliximab, etanercept, efalizumab, alefacept, adalimumab, tazarotene
Current Pharmaceutical Design
Title: Advances in Therapy for Psoriasis: An Overview of Infliximab, Etanercept, Efalizumab, Alefacept, Adalimumab, Tazarotene, and Pimecrolimus
Volume: 11 Issue: 2
Author(s): Ritu Saini, William D. Tutrone and Jeffrey M. Weinberg
Affiliation:
Keywords: psoriasis, biologic therapy, t cell, cytokine, infliximab, etanercept, efalizumab, alefacept, adalimumab, tazarotene
Abstract: Psoriasis is a chronic skin disorder that affects approximately 2% of the US and European population. Over the last several years, one of the major focuses in psoriasis research has been the development of biologic therapies for this disease. The aim of these therapies is to provide selective, immunologically directed intervention with fewer side effects than traditional therapies. The goal of this article is to review the progress of the biologic agents which are available, or under investigation for clinical use: infliximab, etanercept, efalizumab, alefacept, and adalimumab. In addition, two other investigational therapies, oral tazarotene and oral pimecrolimus will be discussed. Clinical data for these agents, including the most recent phase II and / or III study results, will be discussed, as well as the most recent safety data
Export Options
About this article
Cite this article as:
Saini Ritu, Tutrone D. William and Weinberg M. Jeffrey, Advances in Therapy for Psoriasis: An Overview of Infliximab, Etanercept, Efalizumab, Alefacept, Adalimumab, Tazarotene, and Pimecrolimus, Current Pharmaceutical Design 2005; 11 (2) . https://dx.doi.org/10.2174/1381612053382232
DOI https://dx.doi.org/10.2174/1381612053382232 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Evaluating Drug Safety in Children and Adolescents with Bipolar Disorder
Current Drug Safety Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract
Current Pharmaceutical Design Psoriatic Arthritis – Review of the Immunologic, Clinic and Therapeutic Aspects of an Inflammatory Systemic Disease
Current Rheumatology Reviews Therapeutic Potential of Targeting Protease Activated Receptors in Cardiovascular Diseases
Current Pharmaceutical Design Hypertension in Pregnancy: Pathophysiology & Management Strategies
Current Pharmaceutical Design JAK2 Inhibitors for Myelofibrosis: Why are They Effective in Patients with and Without JAK2V617F Mutation?
Anti-Cancer Agents in Medicinal Chemistry Immunotherapy of Kidney Cancer
Current Clinical Pharmacology Advances in L-Type Calcium Channel Structures, Functions and Molecular Modeling
Current Medicinal Chemistry New Approaches to Endothelin Receptor Antagonist-Bosentan
Letters in Organic Chemistry Stressing Conditions as Tools to Boost the Biosynthesis of Valuable Plant Natural Products
Recent Patents on Biotechnology Potential Novel Anxiolytic Drugs
Current Pharmaceutical Design A Case of Ischemic Stroke in Acute Promyelocytic Leukemia at Initial Presentation: Relevance of All-Trans Retinoic Acid Treatment
Cardiovascular & Hematological Disorders-Drug Targets Community-Acquired Pneumonia and Outcome: The Importance of Genetics
Current Respiratory Medicine Reviews Inhibition of Brain Ischemia-Caused Notch Activation in Microglia May Contribute to Isoflurane Postconditioning-Induced Neuroprotection in Male Rats
CNS & Neurological Disorders - Drug Targets Recent Patents in the Field of Radioprotector Development: Opportunities and Challenges
Recent Patents on Biotechnology Ligands and Therapeutic Perspectives of Adenosine A2A Receptors
Current Pharmaceutical Design Rationalizing the Study of Plants for the Treatment of Oral Pain
Current Chemical Biology A Review on Role of the Calcium Sensitive Inotropic Agent, Levosimendan and Its Metabolites
Mini-Reviews in Medicinal Chemistry Adenosine and ATP Receptors in the Brain
Current Topics in Medicinal Chemistry Immunotherapeutic Options for Pediatric Malignancies
Current Immunology Reviews (Discontinued)